Which foundational heart failure medications are contraindicated in patients with severe aortic stenosis?

Vasodilators (ACE Inhibitors, ARBs, Nitroprusside) Are NOT Absolutely Contraindicated in Severe AS

The traditional teaching that foundational heart failure medications are contraindicated in severe aortic stenosis is outdated—vasodilators including ACE inhibitors and ARBs can be used safely in most patients with severe AS and heart failure, though careful hemodynamic monitoring is required in decompensated patients.

Key Medication Considerations

Vasodilators (ACE-I/ARBs) - Generally SAFE

• ACE inhibitors and ARBs are NOT contraindicated in severe AS with heart failure, contrary to conventional teaching 1, 2
• These agents may actually be beneficial by:
  • Reducing left ventricular afterload from peripheral vasoconstriction
  • Attenuating pathological LV hypertrophy and fibrosis
  • Improving diastolic dysfunction 1
• Recent evidence shows they are well-tolerated and may slow AS progression 2
• Caveat: Start cautiously with close blood pressure monitoring; avoid in hypotensive patients (MAP <60 mmHg) 3

Nitroprusside - Safe in Selected Patients

• Despite traditional teaching, nitroprusside rapidly improves cardiac function in critically ill AS patients with LV dysfunction 3
• In a study of 25 patients with severe AS (valve area ≤1 cm²), EF ≤0.35, and cardiac index ≤2.2 L/min/m²:
  • Cardiac index improved from 1.60 to 2.52 L/min/m² over 24 hours
  • Well-tolerated with minimal side effects
  • Provides effective bridge to valve replacement 3
• Exclusion criteria: Hypotension requiring pressors or MAP <60 mmHg 3

Beta-Blockers - Use With Caution

• Historically avoided due to concerns about worsening LV dysfunction
• Recent data suggest they may be safe and potentially beneficial 2
• Some evidence shows beta-blockers associated with reduced stenosis severity markers in low-flow, low-gradient AS 4
• Use cautiously in decompensated patients; better tolerated in stable outpatients

SGLT2 Inhibitors - Emerging Role

• Associated with differential reductions in stenosis severity markers in low-flow, low-gradient severe AS 4
• May benefit selected patients with AS and HFpEF overlap 5
• Represents newer GDMT option that appears safe in AS

The ONE True Contraindication

Intra-aortic balloon pump counterpulsation is absolutely contraindicated in acute severe AR (not AS, but important to distinguish) 6

Clinical Algorithm for HF Medications in Severe AS

1. Assess hemodynamic stability first:

   • If hypotensive (MAP <60 mmHg) or requiring pressors → avoid vasodilators initially
   • If stable → vasodilators are safe to initiate

2. Start vasodilators (ACE-I/ARB) with:

   • Low initial doses
   • Close BP monitoring for first 24-48 hours
   • Gradual uptitration as tolerated

3. Consider beta-blockers in stable patients, particularly if concurrent CAD or arrhythmias

4. Add SGLT2 inhibitors especially if HFpEF phenotype present

5. For decompensated patients requiring ICU care:

   • Nitroprusside is safe and effective despite traditional teaching
   • Provides bridge to definitive valve replacement
   • Requires invasive hemodynamic monitoring 3

Common Pitfalls to Avoid

• Don't reflexively withhold ACE-I/ARBs based on outdated teaching—you're denying patients potentially beneficial therapy
• Don't assume all vasodilators are dangerous—the data show safety when used appropriately with monitoring
• Don't confuse acute AR with AS—the contraindications differ (IABP contraindicated in AR, not AS) 6
• Don't delay valve replacement while optimizing medical therapy—definitive treatment is still AVR/TAVR

The paradigm has shifted: severe AS is no longer an absolute contraindication to standard heart failure medications, but rather requires thoughtful application with appropriate monitoring 3, 1, 2.